The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.
Treating pancreatic ductal adenocarcinoma (PDAC) remains a major hurdle in the field of oncology. Less than half of patients respond to frontline chemotherapy and the pancreatic tumor microenvironment limits the efficacy of immunotherapeutic approaches. Targeted therapies could serve as effective tr...
Main Authors: | Matthew Brown, Wanbin Zhang, Deyue Yan, Rajath Kenath, Le Le, He Wang, Daniel Delitto, David Ostrov, Keith Robertson, Chen Liu, Kien Pham |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0226917 |
Similar Items
-
Targeting Pancreatic Ductal Adenocarcinoma (PDAC)
by: Sofia Parrasia, et al.
Published: (2021-01-01) -
Imaging p53 in Pancreatic Ductal Adenocarcinoma (PDAC)
by: Koustoulidou, S, et al.
Published: (2016) -
Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
by: Natalia Michalak, et al.
Published: (2023-06-01) -
Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
by: Jannat Pervin, et al.
Published: (2023-10-01) -
Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
by: Hao Chen, et al.
Published: (2023-11-01)